Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease.

Su J, Li J, Yu Q, Xu X, Wang J, Yang J, Li X, Chen X.

J Clin Lab Anal. 2019 Mar 19:e22867. doi: 10.1002/jcla.22867. [Epub ahead of print]

PMID:
30891852
2.

Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients.

Su J, Li X, Yu Q, Liu Y, Wang Y, Song H, Cui H, Du W, Fei X, Liu J, Lin S, Wang J, Zheng W, Zhong J, Zhang L, Tong M, Xu J, Chen X.

Biomed Res Int. 2014;2014:450814. doi: 10.1155/2014/450814. Epub 2014 Mar 18.

3.

Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention.

Lei HP, Yu XY, Wu H, Kang YH, Zhong WP, Cai LY, Zhang MZ, Chen JY, Mai LP, Ding QS, Yang M, Zhong SL.

Clin Pharmacokinet. 2018 Jul;57(7):817-829. doi: 10.1007/s40262-017-0595-4.

PMID:
28875477
4.

The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population.

Su J, Yu Q, Zhu H, Li X, Cui H, Du W, Ji L, Tong M, Zheng Y, Xu H, Zhang J, Zhu Y, Xia Y, Liu T, Yao Q, Yang J, Chen X, Yu J.

PLoS One. 2017 Mar 30;12(3):e0174511. doi: 10.1371/journal.pone.0174511. eCollection 2017.

5.

Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.

Kreutz RP, Nystrom P, Kreutz Y, Miao J, Desta Z, Breall JA, Li L, Chiang C, Kovacs R, Flockhart DA, Jin Y.

Clin Pharmacol. 2012;4:13-20. doi: 10.2147/CPAA.S27822. Epub 2012 Feb 20.

6.

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann FJ.

Circ Cardiovasc Genet. 2011 Aug 1;4(4):429-36. doi: 10.1161/CIRCGENETICS.111.960112. Epub 2011 Jun 17.

PMID:
21685174
7.

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.

Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneetrithep B, Likidlilid A.

PLoS One. 2014 Oct 16;9(10):e110188. doi: 10.1371/journal.pone.0110188. eCollection 2014.

8.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
9.

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.

Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):422-8. doi: 10.1161/CIRCINTERVENTIONS.111.963025. Epub 2011 Oct 4.

PMID:
21972404
10.

Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.

Nishio R, Shinke T, Otake H, Nakagawa M, Inoue T, Hariki H, Osue T, Taniguchi Y, Iwasaki M, Hiranuma N, Konishi A, Kinutani H, Kuroda M, Hirata K.

Thromb Res. 2013 Nov;132(5):558-64. doi: 10.1016/j.thromres.2013.09.008. Epub 2013 Sep 13.

PMID:
24080149
11.

Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.

Tang XF, Wang J, Zhang JH, Meng XM, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yuan JQ, Yang YJ.

Eur J Clin Pharmacol. 2013 May;69(5):1103-12. doi: 10.1007/s00228-012-1446-8. Epub 2012 Nov 14.

PMID:
23150151
12.

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.

Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C.

Thromb Haemost. 2013 Dec;110(6):1223-31. doi: 10.1160/TH13-03-0263. Epub 2013 Sep 5.

PMID:
24009042
13.

PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.

Li X, Zhang L, Chen X, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Xu Q, Zhang Y, Li Y, Lu C, Yin T.

Thromb Res. 2013 Oct;132(4):444-9. doi: 10.1016/j.thromres.2013.08.004. Epub 2013 Aug 9.

PMID:
23993903
14.

Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D.

Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19. Erratum in: Nat Med. 2011 Sep;17(9):1153.

PMID:
21170047
15.
16.

The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.

Saydam F, Değirmenci İ, Birdane A, Özdemir M, Ulus T, Özbayer C, Çolak E, Ata N, Güneş HV.

Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):29-36. doi: 10.1111/bcpt.12763. Epub 2017 Mar 14.

17.

Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.

Siasos G, Oikonomou E, Zaromitidou M, Kioufis S, Kokkou E, Mourouzis K, Vlasis K, Vavuranakis M, Stone PH, Papavassiliou AG, Tousoulis D.

Atherosclerosis. 2015 Sep;242(1):102-8. doi: 10.1016/j.atherosclerosis.2015.07.009. Epub 2015 Jul 11.

PMID:
26188531
18.

Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.

Olędzki S, Kornacewicz-Jach Z, Safranow K, Kiedrowicz R, Gawrońska-Szklarz B, Jastrzębska M, Gorący J.

Eur J Clin Pharmacol. 2017 Sep;73(9):1085-1094. doi: 10.1007/s00228-017-2271-x. Epub 2017 Jun 6.

PMID:
28589365
19.

The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease.

Li XG, Ma N, Wang B, Li XQ, Mei SH, Zhao K, Wang YJ, Li W, Zhao ZG, Sun SS, Miao ZR.

Sci Rep. 2016 Sep 30;6:34570. doi: 10.1038/srep34570.

20.

Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.

Yang J, Zhou JS, Tan J, He BS, Zou JJ.

Pharmazie. 2012 Dec;67(12):1026-9.

PMID:
23346768

Supplemental Content

Support Center